Incyte has secured priority‑review approval from the Australian Therapeutic Goods Administration for NIKTIMVO (axatilimab) to treat chronic graft‑versus‑host disease (cGVHD) after failure of at least two prior systemic therapies. The approval, granted on May 3 2026, expands the drug’s commercial reach to Australia, New Zealand and Singapore through an exclusive partnership with Specialised Therapeutics.
The decision follows the pivotal Phase 2 AGAVE‑201 trial, which enrolled 241 patients with refractory cGVHD and demonstrated a 74 % overall response rate at the approved dose of 0.3 mg/kg every two weeks. Sixty percent of responders maintained their response at 12 months, underscoring the durability of the benefit.
Incyte’s role in the Australasian launch is focused on development, manufacture and supply, while Specialised Therapeutics will handle regulatory compliance, distribution, local marketing and medical affairs. The partnership positions Incyte to capture a market that currently relies on limited options such as ruxolitinib and belumosudil.
The Australian market for cGVHD is sizable, with roughly 600 allogeneic stem‑cell transplants performed annually and an estimated 40‑50 % incidence of cGVHD. Although a specific market‑size estimate for NIKTIMVO is not yet disclosed, the approval opens a pathway to a potentially multi‑million‑dollar opportunity pending PBS listing.
Reimbursement status remains pending; Specialised Therapeutics is actively pursuing inclusion on the Pharmaceutical Benefits Scheme, and the drug is not yet listed. Successful listing would broaden patient access and accelerate commercial uptake.
The approval is a key milestone in Incyte’s global rollout strategy, following the U.S. FDA approval in August 2024. It strengthens the company’s position in the chronic GVHD segment, a therapeutic area with high unmet need and limited treatment options, and adds a new revenue stream to the company’s immunology and hematology portfolio.
Incyte’s Q1 2026 earnings, released on April 28 2026, highlighted a 20 % year‑over‑year increase in net sales driven by strong demand for core products and contributions from newer launches, including NIKTIMVO. The company reaffirmed its full‑year guidance, signaling confidence in continued growth as new indications and markets mature.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.